Tumor resistance to CD8+ T cell-based therapeutic vaccination

• Authors: Y. Huang , S. Shah , L. Qiao
• Languages of publication: EN

Abstracts

EN

CD8+ cytotoxic T lymphocytes (CTLs) play an important role in antitumor immunity. Induction of tumor-specific CTLs is one major strategy for tumor immunotherapy. However, therapeutic vaccinations used to treat firmly established tumors are generally ineffective. A thorough understanding of the mechanisms underlying tumor resistance to CTL-based therapeutic vaccination is very important in the tumor immunology field. There are two main mechanisms by which tumors develop resistance to CTL-based therapeutic vaccinations. One is that tumors induce peripheral tolerance of tumor-specific CD8+ T cells. The other is that tumor cells themselves develop immune evasion mechanisms to prevent recognition and killing by CTLs. This review focuses on recently reported cellular and molecular mechanisms of CD8+ T cell tolerance and immune evasion in tumors and discusses about the possibilities to improve tumor immunotherapy.

Keywords

EN

IMMUNOTHERAPY; LYMPHOCYTET; TUMOR; VACCINATION

Discipline

• IMMUNOLOGY: IMMUNOLOGY

• Publisher: Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences
• Journal: Archivum Immunologiae et Therapiae Experimentalis
• Year: 2007
• Volume: 55
• Issue: 4
• Pages: 205-217

Contributors

author

Y. Huang

author

S. Shah

author

L. Qiao

• Document Type: REVIEW
• Publication order reference: Liang Qiao, Division of Developmental Immunology, The La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA